GAG Mimetics Targeting IL-13 Binding Pockets
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods struggle to effectively identify and target conformationally active pockets on therapeutic molecules, particularly for inflammatory modulators like IL-13, which are crucial for treating chronic inflammatory diseases such as asthma and COPD, due to the complexity of their interactions with GAGs and receptor complexes.
Innovation Solution
Development of GAG-like molecules or polyanionic glycoconjugates that bind to specific sites on IL-13, blocking its interaction with receptors, thereby modulating its activity and function, using structural models to identify sulfate binding regions and affinity sites on IL-13.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If computational algorithms are used for in silico screening to identify target molecules, then the rational drug design process is improved, but the identification of conformationally active pockets and binding sites becomes more difficult due to molecular complexity
Solution Approach 1:
The patent uses GAG (glycosaminoglycan) molecules as intermediary substances to bridge the gap between computational screening and actual target identification. By introducing GAGs that naturally bind to IL-13 and related cytokines, the invention creates a physical mediator that highlights conformationally active pockets and binding sites, making them detectable through experimental assays rather than relying solely on complex computational algorithms
Solution Approach 2:
The invention creates simplified copies or models of the complex cytokine-GAG interaction system by using structurally characterized GAG sequences with known binding properties. These standardized GAG molecules serve as reproducible probes that copy the essential binding features, allowing researchers to systematically identify target sites without being overwhelmed by the full complexity of natural biological systems
2Reliability
If GAG molecules are used to bind to IL-13, then the interaction with receptor complexes is blocked and therapeutic effect is improved, but the complexity of molecular interactions increases
Solution Approach 1:
The patent extracts and isolates the specific GAG-IL-13 binding interaction from the complex web of cytokine-receptor-GAG interactions. By focusing on and removing only the essential GAG-IL-13 binding event, the invention simplifies the therapeutic mechanism while maintaining efficacy, allowing the GAG molecule to selectively block IL-13 without requiring modulation of the entire receptor complex system
Solution Approach 2:
The invention applies local quality by designing GAG molecules with specific structural characteristics at particular regions that are optimized for binding to IL-13. Rather than requiring complex global interactions, the therapeutic effect is achieved through localized high-affinity binding at specific conformationally active pockets on the IL-13 molecule, reducing overall molecular complexity while maintaining reliability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These GAG mimetics effectively inhibit IL-13 signaling, offering potential therapeutic benefits for inflammatory diseases, fibrosis, and cancer by blocking the formation of the IL-4Rα/IL-13Rα1 complex, thus providing a targeted approach to managing conditions like asthma and COPD.
Implementation Method 1
GAG-like molecules or polyanionic glycoconjugates that bind to specific sites on IL-13, blocking its interaction with receptors
Data Source
AI summary
Medicaments in the form of therapeutic molecules including inflammatory modulators are designed and selected. A target site is on Interleukin 13 (IL-13) in which a glycosaminoglycan (GAG) molecule or polyanionic glycoconjugate or anionic polysaccharide modulates IL-13 activity or function. The target site can include amino acids located in the AB loops and/or helix D of human IL-13 or its homolog or derivative. The IL-13 target site is used to design a medicament for modulating physiological processes. Therapeutic and prophylactic compositions can include the designed medicaments.